David Meeker, MD, is stepping down from Cambridge, Mass.-based Sanofi Genzyme at the end of June 2017 as the company’s executive vice president and head, according to the Boston Globe. 1. Bill Sibold ...
Hosted on MSN
Rhythm Pharmaceuticals anticipates IMCIVREE launch in acquired hypothalamic obesity with $416M cash position
David Meeker, Chairman, President & CEO, highlighted "strong growth and continued momentum during the third quarter as we prepare to launch IMCIVREE in acquired hypothalamic obesity pending FDA ...
Dr. David Meeker, CEO of Rhythm Pharma, says tariffs won't directly impact them but could stress the biotech sector. He warns FDA layoffs may slow drug approvals for rare diseases. Got a confidential ...
Hosted on MSN
Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment
CEO David Meeker highlighted progress in the Phase 3 trial for acquired hypothalamic obesity (HO) and confirmed plans to file with the FDA in Q3 2025. He expressed confidence in the potential of ...
Executive VP Meeker named COO Meeker initiated overhaul of manufacturing operations Genzyme shares fall 1.6 pct after Barclay's downgrade BOSTON, March 30 (Reuters) - Genzyme Corp has named Executive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results